عنوان

Antibody therapy :

3319680374

3319680382

9783319680378

9783319680385

9783319680378

Antibody therapy :

[Book]

substitution -- immunomodulation -- monoclonal immunotherapy /

Paul Imbach, editor.

Cham, Switzerland :

Springer,

[2018]

©2018

1 online resource

Includes bibliographical references.

Intro; Foreword; Contents; About the Editor; Introduction; 1: The Clinical Translation of Intravenous Immunoglobulin from Substitution to Immunomodulation; 1.1 History of New Observations; 1.2 The Translation of IVIG From ITP to Other Autoimmune Disorders; 1.3 The Bridge of Polyclonal and Monoclonal Antibodies; References; Further Reading; Part I: Update of Substitutive and Immunomodulatory Antibodies/ Drugs Indications; 2: From Immune Substitution to Immuno-modulation; 2.1 History; 2.2 IgG for Replacement: How Much?; 2.3 Immunomodulation in Autoimmune Diseases.

2.4 Immunomodulation in Alloimmune Diseases2.5 Immunomodulation in Inflammatory Diseases; 2.6 Expansion to New Indications; References; 3: Manual of Primary and Secondary Immunodeficiencies; 3.1 Introduction; 3.2 X-Linked (Bruton's) Agammaglobulinemia; 3.2.1 Definition and Prevalence; 3.2.2 Pathophysiology; 3.2.3 Clinical Manifestations; 3.2.4 Diagnostics; 3.2.5 Differential Diagnosis; 3.2.6 Therapy; 3.2.7 Prognosis; 3.3 Severe Combined Immunodeficiency (SCID); 3.3.1 Definition and Prevalence; 3.3.2 Pathophysiology; 3.3.2.1 Different Forms; T-B + Variants; T-B-Variants.

3.12.2.2 Hematopoietic Stem Cell Transplantation HSCT3.12.2.3 Solid Organ Transplantation; 3.12.3 HIV Infection in Children; 3.12.4 Preterm Infants; 3.12.5 Geriatrics: Immunosenescence; 3.13 Other Combined Immunodeficiency; 4: Manual of Intravenous and Subcutaneous IgG Indications in Autoimmune Diseases; 4.1 Introduction; 4.2 General Characteristics of Autoimmune Disorders; 4.3 General Characteristics of IVIG as an Immunomodulatory Biological Agent; 4.4 Clinical Categorization of IVIG Indications of Autoimmune and Inflammatory Disorders; 4.5 Hematology.

3.3.3 Clinical Manifestations3.3.4 Diagnostics; 3.3.5 Treatment; 3.4 Hyper-IgM Syndromes; 3.4.1 Pathogenesis; 3.4.2 Clinical Presentation; 3.4.3 Treatment; 3.5 Common Variable Immunodeficiency (CVID); 3.5.1 Incidence and Diagnosis; 3.5.2 Clinical Manifestations; 3.5.3 Treatment; 3.6 Selective Antibody Deficiency; 3.6.1 Definition and Diagnosis; 3.6.2 Treatment; 3.7 Transient Hypogammaglobulinemia of Infancy; 3.7.1 Definition and Diagnosis; 3.7.2 Management; 3.8 Isolated IgG 1-3 Subclass Deficiency; 3.8.1 Management.

3.9 Selective IgA Deficiency with or without IgG2 Deficiency3.10 Wiskott-Aldrich Syndrome (WAS); 3.10.1 Pathogenesis/Etiology; 3.10.2 Clinical Manifestations; 3.10.3 Treatment; 3.11 Ataxia Telangiectasia; 3.11.1 Pathophysiology/Etiology; 3.11.2 Clinical Manifestation; 3.11.3 Treatment; 3.12 Secondary Immunodeficiency; 3.12.1 Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Treatment of Related Secondary Immunodeficiency in Patients with Hematologic or with Solid Tumor Malignancy with or without Transplantation; 3.12.2 Specific Aspects; 3.12.2.1 CLL and MM.

0

8

8

8

8

This practical manual, written by well-known experts, reviews current indications for the use of IgG concentrates and some other modern immunomodulators and provides fundamental information on present-day immunomodulation in patients (and mice). The book opens by tracing the transition from IgG substitution to IgG immunomodulation and providing expert updates on immunomodulatory indications in autoimmune and inflammatory disorders, including hematologic, neurologic, dermatologic, and other diseases. Basic aspects of IgG concentrates, including methods of production, safety, currently available products, and mechanisms of action, are then discussed. An entire chapter is devoted to the different aspects of immunomodulatory IgG treatment in the bleeding disorder immune thrombocytopenia (ITP). Finally, the transition from polyclonal to monoclonal antibody (mAb) treatment is addressed in detail, covering mAb development, methods, mechanisms of action, adverse effects, and more. Particular attention is paid to the example of anti-CD20 (B-cell) antibody.

Springer Nature

com.springer.onix.9783319680385

9783319680378

Immunoglobulins-- Therapeutic use.

Antibodies, Monoclonal-- therapeutic use.

Immunoglobulin G-- therapeutic use.

Immunologic Factors.

Immunomodulation.

Haematology.

HEALTH & FITNESS-- Diseases-- General.

Immunoglobulins-- Therapeutic use.

Immunology.

MEDICAL-- Clinical Medicine.

MEDICAL-- Diseases.

MEDICAL-- Evidence-Based Medicine.

MEDICAL-- Internal Medicine.

Oncology.

HEA-- 039000

MED-- 014000

MED-- 022000

MED-- 045000

MED-- 112000

MJF

Imbach, Paul

20200823102501.0

pn

[Book]

Y